Innoviva Subsidiary Nortiva Bio Launches as Clinical-Stage Biopharma with LYNX Drug Delivery Platform

Corporate Action
โดย Insider Monkey·Read original
Summary · why it matters

Innoviva announced that its wholly owned subsidiary Nortiva Bio has launched as a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using the proprietary LYNX drug delivery platform. Innoviva acquired the LYNX platform from Lyndra Therapeutics in 2025, and it is designed to transform daily pills into single-dose therapies lasting up to a month across multiple therapeutic areas. The platform is built on foundational science from the labs of Robert Langer and Gio Traverso at MIT and has undergone years of clinical validation, including a successful Phase 3 study.

Impact on stocks 1

Aging Population▲ · 1 stocks
Innoviva Inc
INVA
▲ PositiveTechnologyrelevance

Innoviva's subsidiary launches with LYNX platform, a clinical-stage drug delivery technology with Phase 3 validation.

Off-coverage companies 2

Nortiva Bio, Inc.Private▲ Positive
Technologyrelevance

Nortiva Bio launches as a clinical-stage biopharma with the LYNX platform, a positive development for the subsidiary.

Lyndra Therapeutics, Inc.Private± Mixed
relevance

© 2026 MarketDXNews